According to a study in the New England Journal of Medicine, Merck & Co.'s Fosamax drug, primarily used for the treatment of osteoporosis in women, is also useful in treating the disease in men. The two-year study, led by a team of researchers from the Oregon Health Sciences University, found that the drug was effective in increasing bone density in men, particularly in the spine and hip. Merck announced earlier this year that it is seeking approval from the US Food and Drug Administration to sell the drug to men. For more information, visit www.merck.com.
The Value of Certification in Infection Prevention and Control: Why Is it important?
May 14th 2024Certification in infection prevention and control is essential for career growth, higher salaries, and improved patient outcomes. Learn why certification matters from Shazia Irum, MSC, MBA, RN, CIC, CPHQ, CBIC Ambassador in Saudi Arabia.